**Table S2. Overall and Individual System Scores by Provider’s Gender**

|  | **All Groups** | **FEMALE** | **MALE** | **P-value\*\*** | **Test** |
| --- | --- | --- | --- | --- | --- |
|  | N=77 | N=33 | N=44 |  |  |
| **OVERALL\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 8.0(6.0-13.0) | 9.0(6.0-13.0) | 8.0(6.0-13.0) |  |  |
| **I\_UPDATED\_IMMU** |  |  |  | 0.37 | Chi-square |
| NO | 4(5.2%) | 1(3.0%) | 3(6.8%) |  |  |
| YES | 50(64.9%) | 24(72.7%) | 26(59.1%) |  |  |
| Missing | 23(29.9%) | 8(24.2%) | 15(34.1%) |  |  |
| **I\_IMMU\_NA** |  |  |  | 0.20 | Chi-square |
| NO | 60(77.9%) | 28(84.8%) | 32(72.7%) |  |  |
| YES | 17(22.1%) | 5(15.2%) | 12(27.3%) |  |  |
| **OC\_CLINCAL\_ASS** |  |  |  | 0.06 | Chi-square |
| NO | 51(66.2%) | 18(54.5%) | 33(75.0%) |  |  |
| YES | 26(33.8%) | 15(45.5%) | 11(25.0%) |  |  |
| **OC\_EXAM** |  |  |  | <0.01 | Chi-square |
| NO | 60(77.9%) | 21(63.6%) | 39(88.6%) |  |  |
| YES | 17(22.1%) | 12(36.4%) | 5(11.4%) |  |  |
| **OCULAR\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 0.0(0.0-2.0) | 1.0(0.0-2.0) | 0.0(0.0-2.0) |  |  |
| **OR\_EDU** |  |  |  | 0.42 | Chi-square |
| NO | 70(90.9%) | 29(87.9%) | 41(93.2%) |  |  |
| YES | 7(9.1%) | 4(12.1%) | 3(6.8%) |  |  |
| **OR\_EXAM** |  |  |  | 0.62 | Chi-square |
| NO | 6(7.8%) | 2(6.1%) | 4(9.1%) |  |  |
| YES | 71(92.2%) | 31(93.9%) | 40(90.9%) |  |  |
| **OR\_DENTAL\_EX** |  |  |  | 0.02 | Chi-square |
| NO | 70(90.9%) | 27(81.8%) | 43(97.7%) |  |  |
| YES | 7(9.1%) | 6(18.2%) | 1(2.3%) |  |  |
| **ORAL\_SCORE** |  |  |  | 0.03 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-3.0) | 1.0(0.0-3.0) |  |  |
| **RES\_EXAM** |  |  |  | 0.73 | Chi-square |
| NO | 3(3.9%) | 1(3.0%) | 2(4.5%) |  |  |
| YES | 74(96.1%) | 32(97.0%) | 42(95.5%) |  |  |
| **RES\_TOBACCO** |  |  |  | 0.42 | Chi-square |
| NO | 72(93.5%) | 30(90.9%) | 42(95.5%) |  |  |
| YES | 5(6.5%) | 3(9.1%) | 2(4.5%) |  |  |
| **RES\_SYM\_ASS** |  |  |  | 0.38 | Chi-square |
| NO | 1(1.3%) | 0 | 1(2.3%) |  |  |
| YES | 76(98.7%) | 33(100.0%) | 43(97.7%) |  |  |
| **RES\_PFT** |  |  |  | 0.84 | Chi-square |
| NO | 2(2.6%) | 1(3.0%) | 1(2.3%) |  |  |
| YES | 75(97.4%) | 32(97.0%) | 43(97.7%) |  |  |
| **RESP\_SCORE** |  |  |  | 0.51 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 3.0(1.0-4.0) | 3.0(2.0-4.0) | 3.0(1.0-4.0) |  |  |
| **CV\_EXAM** |  |  |  | 0.73 | Chi-square |
| NO | 3(3.9%) | 1(3.0%) | 2(4.5%) |  |  |
| YES | 74(96.1%) | 32(97.0%) | 42(95.5%) |  |  |
| **CV\_RISK\_EVAL** |  |  |  | <0.01 | Chi-square |
| NO | 49(63.6%) | 15(45.5%) | 34(77.3%) |  |  |
| YES | 28(36.4%) | 18(54.5%) | 10(22.7%) |  |  |
| **CV\_ED** |  |  |  | 0.03 | Chi-square |
| NO | 66(85.7%) | 25(75.8%) | 41(93.2%) |  |  |
| YES | 11(14.3%) | 8(24.2%) | 3(6.8%) |  |  |
| **CV\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 2.0(0.0-3.0) | 1.0(0.0-3.0) |  |  |
| **HEP\_LFT** |  | All patients got YES. |  |  |  |
| **HEP\_HEPBC** |  |  |  | 0.42 | Chi-square |
| NO | 72(93.5%) | 30(90.9%) | 42(95.5%) |  |  |
| YES | 5(6.5%) | 3(9.1%) | 2(4.5%) |  |  |
| **HEP\_VIRALLOAD** |  |  |  | 0.84 | Chi-square |
| NO | 75(97.4%) | 32(97.0%) | 43(97.7%) |  |  |
| YES | 2(2.6%) | 1(3.0%) | 1(2.3%) |  |  |
| **HEP\_FERRITIN\_ASS** |  |  |  | 0.24 | Chi-square |
| NO | 65(84.4%) | 26(78.8%) | 39(88.6%) |  |  |
| YES | 12(15.6%) | 7(21.2%) | 5(11.4%) |  |  |
| **HEP\_FERRTIN\_OR\_PREABNL** |  |  |  | 0.17 | Chi-square |
| NO CHCK 4 ABNORMAL | 3(3.9%) | 1(3.0%) | 2(4.5%) |  |  |
| NO | 64(83.1%) | 25(75.8%) | 39(88.6%) |  |  |
| YES | 10(13.0%) | 7(21.2%) | 3(6.8%) |  |  |
| **HEPA\_SCORE** |  |  |  | 0.13 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 0.0(0.0-4.0) | 0.0(0.0-4.0) | 0.0(0.0-2.0) |  |  |
| **RENAL\_BP** | All patients got YES |  |  |  |  |
| **RENAL\_BUN\_CR** | All patients got YES |  |  |  |  |
| **RENAL\_SCORE** |  |  |  | 1.00 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 2.0(2.0-2.0) | 2.0(2.0-2.0) | 2.0(2.0-2.0) |  |  |
| **MS\_EVAL\_MS\_WEAKNESS** |  |  |  | 0.05 | Chi-square |
| NO | 69(89.6%) | 27(81.8%) | 42(95.5%) |  |  |
| YES | 8(10.4%) | 6(18.2%) | 2(4.5%) |  |  |
| **MS\_COUNSEL\_PHY** |  |  |  | 0.12 | Chi-square |
| NO | 68(88.3%) | 27(81.8%) | 41(93.2%) |  |  |
| YES | 9(11.7%) | 6(18.2%) | 3(6.8%) |  |  |
| **MS\_COUNSEL\_ON\_FALL** |  |  |  | 0.38 | Chi-square |
| NO | 76(98.7%) | 33(100.0%) | 43(97.7%) |  |  |
| YES | 1(1.3%) | 0 | 1(2.3%) |  |  |
| **MS\_COUNSEL\_CA\_VITD** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 21(63.6%) | 40(90.9%) |  |  |
| YES | 16(20.8%) | 12(36.4%) | 4(9.1%) |  |  |
| **MS\_ASS\_NEED\_DEXA** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 21(63.6%) | 40(90.9%) |  |  |
| YES | 16(20.8%) | 12(36.4%) | 4(9.1%) |  |  |
| **MS\_DEXA** |  |  |  | <0.01 | Chi-square |
| NO | 61(79.2%) | 21(63.6%) | 40(90.9%) |  |  |
| YES | 16(20.8%) | 12(36.4%) | 4(9.1%) |  |  |
| **MS\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 0.0(0.0-5.0) | 1.0(0.0-5.0) | 0.0(0.0-4.0) |  |  |
| **CNS\_EXAM** |  |  |  | 0.95 | Chi-square |
| NO | 30(39.0%) | 13(39.4%) | 17(38.6%) |  |  |
| YES | 47(61.0%) | 20(60.6%) | 27(61.4%) |  |  |
| **CNS\_EVAL\_COGNITIVE** |  |  |  | 0.04 | Chi-square |
| NO | 74(96.1%) | 30(90.9%) | 44(100.0%) |  |  |
| YES | 3(3.9%) | 3(9.1%) | 0 |  |  |
| **CNS\_SCORE** |  |  |  | 0.68 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 1.0(0.0-2.0) | 1.0(0.0-2.0) | 1.0(0.0-1.0) |  |  |
| **ENDO\_TFT** |  |  |  | <0.01 | Chi-square |
| NO | 22(28.6%) | 3(9.1%) | 19(43.2%) |  |  |
| YES | 55(71.4%) | 30(90.9%) | 25(56.8%) |  |  |
| **ENDO\_ASS\_GONADAL\_FUNCTION** |  |  |  | 0.41 | Chi-square |
| NO | 68(88.3%) | 28(84.8%) | 40(90.9%) |  |  |
| YES | 9(11.7%) | 5(15.2%) | 4(9.1%) |  |  |
| **ENDO\_GONADAL\_FN\_TEST** |  |  |  | 1.00 | Chi-square |
| NO | 70(90.9%) | 30(90.9%) | 40(90.9%) |  |  |
| YES | 7(9.1%) | 3(9.1%) | 4(9.1%) |  |  |
| **ENDO\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-3.0) | 1.0(0.0-3.0) |  |  |
| **MUCU\_SKINEXAM** |  |  |  | 0.89 | Chi-square |
| NO | 24(31.2%) | 10(30.3%) | 14(31.8%) |  |  |
| YES | 53(68.8%) | 23(69.7%) | 30(68.2%) |  |  |
| **MUCU\_COUNSEL\_SUN\_EXPOSURE** |  |  |  | 0.02 | Chi-square |
| NO | 70(90.9%) | 27(81.8%) | 43(97.7%) |  |  |
| YES | 7(9.1%) | 6(18.2%) | 1(2.3%) |  |  |
| **MU\_CU\_GYNE\_EXAM** |  |  |  | 0.40 | Chi-square |
| NO | 74(96.1%) | 31(93.9%) | 43(97.7%) |  |  |
| YES | 3(3.9%) | 2(6.1%) | 1(2.3%) |  |  |
| **MUCU\_SCORE** |  |  |  | 0.23 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 1.0(0.0-3.0) | 1.0(0.0-3.0) | 1.0(0.0-3.0) |  |  |
| **SECOND\_\_CANCER\_COUNSEL** |  |  |  | <0.01 | Chi-square |
| NO | 67(87.0%) | 25(75.8%) | 42(95.5%) |  |  |
| YES | 10(13.0%) | 8(24.2%) | 2(4.5%) |  |  |
| **SECOND\_CANCER\_SCREENING** |  |  |  | 0.03 | Chi-square |
| NO | 66(85.7%) | 25(75.8%) | 41(93.2%) |  |  |
| YES | 11(14.3%) | 8(24.2%) | 3(6.8%) |  |  |
| **SECOND\_CANCER\_SCORE** |  |  |  | <0.01 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 0.0(0.0-2.0) | 0.0(0.0-2.0) | 0.0(0.0-2.0) |  |  |
| **PSYCH\_QOL\_SCREENING** |  |  |  | 0.02 | Chi-square |
| NO | 73(94.8%) | 29(87.9%) | 44(100.0%) |  |  |
| YES | 4(5.2%) | 4(12.1%) | 0 |  |  |
| **PSYCH\_INQUIRY\_FAMILY** |  |  |  | 0.38 | Chi-square |
| NO | 76(98.7%) | 33(100.0%) | 43(97.7%) |  |  |
| YES | 1(1.3%) | 0 | 1(2.3%) |  |  |
| **PSYCH\_INQUIRY\_SEXUAL\_FUNCTION** |  |  |  | 0.38 | Chi-square |
| NO | 76(98.7%) | 33(100.0%) | 43(97.7%) |  |  |
| YES | 1(1.3%) | 0 | 1(2.3%) |  |  |
| **PSYCH\_INQUIRY\_SUBSTANCE\_ABUSE** |  |  |  | 0.38 | Chi-square |
| NO | 76(98.7%) | 33(100.0%) | 43(97.7%) |  |  |
| YES | 1(1.3%) | 0 | 1(2.3%) |  |  |
| **PSYCH\_SCORE** |  |  |  | 0.43 | Rank-Sum Tests |
| N of Observed | 77 | 33 | 44 |  |  |
| Median(Min-Max) | 0.0(0.0-1.0) | 0.0(0.0-1.0) | 0.0(0.0-1.0) |  |  |
|  |  |  |  |  |  |